ArticlePsychiatry investigation2025
Diagnostic Value of Electroencephalography Features and Serum Neurotrophic Factors in Differentiating Attention-Deficit/Hyperactivity Disorder Subtypes.
Article in Psychiatry investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveAttention-deficit/hyperactivity disorder (ADHD) includes three subtypes: inattentive type (ADHD-I), hyperactive/impulsive type (ADHD-HI), and combined type (ADHD-C). Diagnosis mainly relies on subjective behavioral rating scales, lacking objective biomarkers. Electroencephalography (EEG) and serum neurotrophic factors-brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and neurotrophin-3 (NTF3)-may aid subtype differentiation. This study evaluates their combined diagnostic value in children with ADHD.
methodsA retrospective cohort of 322 children aged 6-12 years diagnosed with ADHD based on DSM-5 criteria was analyzed. EEG recordings were processed using Fast Fourier Transform to extract frequency band powers and P300 wave features. Serum levels of BDNF, NGF, GDNF, and NTF3 were measured via ELISA. Analysis of variance (ANOVA), multivariate regression, and ROC curve analyses were performed to assess diagnostic performance.
resultsADHD-I patients exhibited elevated frontal θ power, higher θ/β ratios, prolonged P300 latency, and reduced P300 amplitude. ADHD-HI patients demonstrated increased β power in parietal regions and elevated NGF and NTF3 levels. Multivariate analysis identified θ power, θ/β ratio, NGF, NTF3, and P300 amplitude area as independent predictors for subtype differentiation. Combined EEG and serum markers yielded an area under the curve (AUC) (0.90) in distinguishing ADHD-I from ADHD-HI.
conclusionThe integration of EEG features and neurotrophic factor profiles offers high diagnostic accuracy in differentiating ADHDI from ADHD-HI and moderate accuracy for the other subtype comparisons. These findings support the development of objective biomarker- based diagnostic tools for precision psychiatry in ADHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.